The path from ADC development to commercial manufacturing is becoming increasingly complex, requiring specialized expertise, scalable manufacturing capabilities, and resilient supply chains. As more antibody-drug conjugates (ADCs) progress toward commercialization, selecting the right development and manufacturing partner can play a critical role in reducing risk and accelerating program success.
In this webinar recording, Iwan Bertholjotti, Senior Director, Commercial Development, shares insights into how an integrated approach to ADC development and manufacturing can support a seamless transition from clinical development to commercial supply. Learn how connected capabilities across bioconjugation, payload-linker development, process scale-up, technology transfer, and commercial manufacturing can help simplify development, improve operational efficiency, and mitigate CMC and supply chain challenges.
Discover how partnering with an experienced ADC CDMO can provide the capacity, technical expertise, and manufacturing flexibility needed to support long-term commercial success. The session also explores strategies for streamlining the journey from early development through commercialization, helping biopharmaceutical companies bring innovative bioconjugate therapies to patients faster and with greater confidence.
